ストックスクリーナーアプリを入手
2.30
4.56%
-0.11
前日終値:
$2.41
開ける：
$2.41
24時間の取引高:
867.53K
Relative Volume:
0.75
時価総額：
$373.90M
収益：
$10.00M
当期純損益:
$-29.47M
株価収益率:
-11.50
EPS:
-0.2
ネットキャッシュフロー:
$-21.55M
1週間 パフォーマンス:
-3.36%
1か月 パフォーマンス:
-6.12%
6か月 パフォーマンス:
-44.44%
1年 パフォーマンス:
-30.30%
1日の値動き範囲:
$2.2801
$2.4766
1週間の範囲:
$2.2249
$2.73
52週間の値動き範囲:
$2.2249
$5.02
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
名前
Mereo Biopharma Group Plc Adr
セクター
電話
4403330237300
住所
ONE CAVENDISH PLACE, LONDON
MREO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
2.30 | 373.90M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2023-10-13 | 再開されました | BTIG Research | Buy |
| 2022-08-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 開始されました | BTIG Research | Buy |
| 2021-04-05 | 開始されました | Needham | Buy |
すべてを表示
Mereo Biopharma Group Plc Adr (MREO) 最新ニュース
Mereo BioPharma stock hits 52-week low at $2.25 - Investing.com
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights - GlobeNewswire
Mereo BioPharma Secures 3-Year Cash Runway While Pushing Phase 3 Studies Forward - StockTitan
Closing Bell Recap: WANG & LEE Group Inc (WLGS) Ends at 0.43, Reflecting a -42.70 Downturn - The Dwinnex
Pfizer to Exit Sensodyne-Maker Haleon With Final Stake Sale - MSN
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Mereo BioPharma’s SWOT analysis: setrusumab, alvelestat drive rare disease stock potential - Investing.com India
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential - Barchart
How Do Things Look For Mereo Biopharma Group Plc ADR (NASDAQ: MREO) In The Short-Term? - Stocks Register
Mereo BioPharma stock hits 52-week low at $2.52 By Investing.com - Investing.com South Africa
Mereo BioPharma stock hits 52-week low at $2.52 - Investing.com India
Prepare Yourself for Liftoff: Mereo Biopharma Group Plc ADR (MREO) - SETE News
There is no doubt that OrganiGram Holdings Inc (OGI) ticks all the boxes. - SETE News
Check Out ImmunoPrecise Antibodies Ltd (IPA)’s Trade Data Rather Than the Analysts’ Views - SETE News
Recent Insider Activity Could Benefit Mereo Biopharma Group Plc ADR (MREO) - Knox Daily
Analyzing Digital Turbine Inc (APPS) After Recent Trading Activity - Knox Daily
Market Insights: Mereo Biopharma Group Plc ADR (MREO)’s Notable Drop of -0.66, Closing at 2.99 - The Dwinnex
Daily Market Movement: Twist Bioscience Corp (TWST) Sees a 0.73 Increase, Closing at 52.75 - The Dwinnex
In the Green: Sensata Technologies Holding Plc (ST) Closes at 25.62, Up/Down -5.67 from Previous Day - The Dwinnex
How should investors view Anavex Life Sciences Corporation (AVXL)? - US Post News
Health In Tech Inc (HIT) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Was there any good news for Mereo Biopharma Group Plc ADR (MREO) stock in the last session? - US Post News
It would be worthwhile to take a closer look at Therealreal Inc (REAL) - US Post News
Lemonade Inc (LMND) deserves deeper analysis - US Post News
Form N-CSR FIDELITY CONCORD STREET For: Nov 30 - StreetInsider.com
Verona Pharma stock target upgraded, retains buy on Q4 results - MSN
symbol__ Stock Quote Price and Forecast - CNN
Analyze Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Before Investing. - Stocks Register
Mereo BioPharma Provides Update on Lead Clinical Programs - GlobeNewswire Inc.
Mereo BioPharma's Setrusumab Advances Phase 3 Trial as Alvelestat Gains Key EU Support - StockTitan
How Are Things Looking For Mereo Biopharma Group Plc ADR (NASDAQ: MREO) For The Short Term? - Stocks Register
Crude Oil Down 1%; Webuy Global Shares Spike Higher - Benzinga
Mereo BioPharma's SWOT analysis: rare disease pipeline drives stock potential - Investing.com
Mereo BioPharma's SWOT analysis: rare disease stock poised for growth - Investing.com
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Do investors need to be concerned about Mereo Biopharma Group Plc ADR (MREO)? - US Post News
Mereo Biopharma Group Plc ADR (MREO) gets rating Initiated from Robert W. Baird - Knox Daily
JP Morgan analysts upgrades an Overweight rating for Nucor Corp. (NUE) - Knox Daily
KeyBanc Capital Markets initates Alignment Healthcare Inc (ALHC) stock to a Sector weight - Knox Daily
Trading Day Review: Mereo Biopharma Group Plc ADR (MREO) Loses Momentum, Closing at 4.16 - The Dwinnex
Natera Inc (NTRA) receives a Buy rating from Jefferies - Knox Daily
Barclays initates Reinsurance Group Of America, Inc. (RGA) stock to an Overweight - Knox Daily
Recent Insider Activity Suggests Potential Gains for Mereo Biopharma Group Plc ADR (MREO) - Knox Daily
Potential Price Increase for Portland General Electric Co (POR) After Recent Insider Activity - Knox Daily
Analysts review KLA Corp.’s rating - Knox Daily
Perhaps timely catching Mereo Biopharma Group Plc ADR (MREO) would be a good idea - SETE News
MREO Stock Sees Surge of Approximately 7.32% in Last Five Days - Knox Daily
Stocks of Mereo Biopharma Group Plc ADR (MREO) are poised to climb above their peers - SETE News
Monitoring Mereo Biopharma Group Plc ADR (MREO) after recent insider movements - Knox Daily
Mereo Biopharma Group Plc ADR (MREO)’s stock price in review: A technical analysis - US Post News
Mereo Biopharma Group Plc Adr (MREO) 財務データ
収益
当期純利益
現金流量
EPS
Mereo Biopharma Group Plc Adr (MREO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Scots-Knight Denise | Chief Executive Officer |
Sep 12 '24 |
Sale |
4.47 |
28,611 |
127,968 |
868,967 |
| Lewicki John A. | Chief Scientific Officer |
Sep 13 '24 |
Sale |
4.22 |
10,937 |
46,165 |
78,630 |
| Lewicki John A. | Chief Scientific Officer |
Sep 12 '24 |
Sale |
4.47 |
5,212 |
23,312 |
89,567 |
| Sermon Charles | General Counsel |
Sep 13 '24 |
Sale |
4.22 |
20,946 |
88,413 |
219,061 |
| Sermon Charles | General Counsel |
Sep 12 '24 |
Sale |
4.47 |
9,980 |
44,638 |
240,007 |
| Fox Christine Ann | Chief Financial Officer |
Sep 13 '24 |
Sale |
4.22 |
19,158 |
80,866 |
89,285 |
| Fox Christine Ann | Chief Financial Officer |
Sep 12 '24 |
Sale |
4.47 |
9,128 |
40,827 |
108,443 |
| Hughes-Wilson Alexandra | See Remarks |
Sep 13 '24 |
Sale |
4.22 |
100,312 |
423,417 |
50,475 |
| Hughes-Wilson Alexandra | See Remarks |
Sep 12 '24 |
Sale |
4.47 |
47,798 |
213,786 |
150,787 |
| Sermon Charles | General Counsel |
Sep 11 '24 |
Option Exercise |
0.00 |
65,600 |
0 |
249,987 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):